
PROSTAGLANDINS IN CARDIOVASCULAR AND RENAL FUNCTION

Edited by
ALEXANDER SCRIABINE, M.D.
ALLAN M. LEFER, Ph.D.
FREDERICK A. KUEHL, JR., Ph.D.

PROSTAGLANDINS IN CARDIOVASCULAR AND RENAL FUNCTION

Proceedings of the 20th Annual
A.N. Richards Symposium
of the Physiological Society of Philadelphia
King of Prussia, Pennsylvania, May 8-9, 1978

Edited by

Alexander Scriabine, M.D.
Wyeth Laboratories Inc.
Radnor, Pennsylvania

Allan M. Lefer, Ph.D.
Department of Physiology
Jefferson Medical College
of Thomas Jefferson University
Philadelphia, Pennsylvania

and

Frederick A. Kuehl, Jr., Ph.D.
Merck Institute for Therapeutic Research
Rahway, New Jersey


MTP PRESS LIMITED
International Medical Publishers

Published in the UK and Europe by
MTP Press Limited
Falcon House
Lancaster, England

Published in the US by
SPECTRUM PUBLICATIONS, INC.
175-20 Wexford Terrace
Jamaica, N.Y. 11432

Copyright © 1980 Spectrum Publications, Inc.

All rights reserved. No part of this book may be reproduced in any form, by photostat, microform, retrieval system, or any other means without prior written permission of the copyright holder or his licensee.

ISBN: 0-85200-532-6

Printed in the United States

PROSTAGLANDINS IN CARDIOVASCULAR AND RENAL FUNCTION

Monographs of the Physiological Society of Philadelphia

Volume 1

IMMUNOPHARMACOLOGY

Proceedings of the Conference on Immunopharmacology

Philadelphia, January 27-28, 1975

Marvin E. Rosenthale and Herbert C. Mansmann, Jr., Editors

Volume 2

NEW ANTIHYPERTENSIVE DRUGS

Proceedings of the A.N. Richards Symposium

King of Prussia, Pennsylvania, May 19-20, 1975

Alexander Scriabine and Charles S. Sweet, Editors

Volume 3

PROSTAGLANDINS IN HEMATOLOGY

Proceedings of the International Symposium on

Prostaglandins in Hematology

Philadelphia, March 4-5, 1976

M.J. Silver, J.B. Smith and J.J. Kocsis, Editors

Volume 4

PATHOPHYSIOLOGY AND THERAPEUTICS OF MYOCARDIAL ISCHEMIA

Proceedings of the A.N. Richards Symposium

Philadelphia, May 6-7, 1976

Allan M. Lefer, Gerald J. Kelliher and Michael J. Rovetto, Editors

Volume 5

HISTAMINE RECEPTORS

Proceedings of the A.N. Richards Symposium

Philadelphia, March 21-22, 1977

Tobias O. Yellin, Editor

Volume 6

PROSTAGLANDINS IN CARDIOVASCULAR AND RENAL FUNCTION

Proceedings of the A.N. Richards Symposium

King of Prussia, Pennsylvania, May 8-9, 1978

Alexander Scriabine, Allan M. Lefer

and Frederick A. Kuehl, Jr., Editors

Contributors

U. AXEN
The Upjohn Company
Research Laboratories
Kalamazoo, Michigan

P. J. BAKER
Georgetown University Medical Center
Department of Physiology and Biophysics
Washington, D.C.

W. E. BARNETTE
University of Pennsylvania
Department of Chemistry
Philadelphia, Pennsylvania

T. G. BELL
Michigan State University
Department of Biochemistry
East Lansing, Michigan

H. J. BERGER
Yale University School of Medicine
Cardiology Section
Department of Medicine
New Haven, Connecticut

E. H. BLAINE
Merck Institute for Therapeutic Research
West Point, Pennsylvania

M. C. BLASINGHAM
University of Tennessee
Center for the Health Sciences

Department of Pharmacology
Memphis, Tennessee

N. R. BOHIDAR
Merck Institute for Therapeutic Research
West Point, Pennsylvania

T. BURNS
University of Texas
Health Science Center
Department of Medicine
San Antonio, Texas

M. C. CARRARA
The Hospital for Sick Children
Research Institute
Toronto,
Canada

B. M. CHAPNICK
Tulane University School of Medicine
Department of Pharmacology
New Orleans, Louisiana

G. L. DeGRAAF
The Upjohn Company
Cardiovascular Diseases Research
Kalamazoo, Michigan

D. W. DuCHARME
The Upjohn Company
Cardiovascular Diseases Research
Kalamazoo, Michigan

R. DÜSING
Medizinische Poliklinik
Universität
Bonn
West Germany

E. F. ELLIS
Medical College of Virginia
Department of Pharmacology
Richmond, Virginia

M. EPSTEIN
University of Texas
Health Science Center
Department of Medicine
San Antonio, Texas

S. FADAM
University of Texas
Health Science Center
Department of Medicine
San Antonio, Texas

G. M. FANELLI, JR.
Merck Institute for Therapeutic Research
West Point, Pennsylvania

L. P. FEIGEN
Tulane University School of Medicine
Department of Pharmacology
New Orleans, Louisiana

N. GOOD
Yale University School of Medicine
Department of Medicine
Cardiology Section
New Haven, Connecticut

F. C. GRENIER
Michigan State University
Department of Biochemistry
East Lansing, Michigan

E. A. HAM
Merck Institute for Therapeutic Research
Rahway, New Jersey

P. HEDQVIST
Karolinska Institute
Department of Physiology

Stockholm
Sweden

T. HONOHAN
The Upjohn Company
Research Laboratories
Kalamazoo, Michigan

J. B. HOOK
Michigan State University
Department of Pharmacology and Toxicology
East Lansing, Michigan

W. HSUEH
Washington University Medical School
Department of Pharmacology
St. Louis, Missouri

S. J. HUMPHREY
The Upjohn Company
Cardiovascular Diseases Research
Kalamazoo, Michigan

A. L. HYMAN
Tulane University School of Medicine
Department of Pharmacology
New Orleans, Louisiana

R. JOPPICH
University of Munich
Kinderklinik
Munich,
Germany

P. J. KADOWITZ
Tulane University School of Medicine
Department of Pharmacology
New Orleans, Louisiana

J. P. KOKKO
University of Texas Health Science Center
Southwestern Medical School
Department of Internal Medicine
Dallas, Texas

H. A. KONTOS
Medical College of Virginia
Department of Medicine
Richmond, Virginia

M. C. KOSS
University of Oklahoma
Health Sciences Center
Department of Pharmacology
Oklahoma City, Oklahoma

F. A. KUEHL, JR.
Merck Institute for Therapeutic Research
Rahway, New Jersey

J. B. LEE
State University of New York at Buffalo
Department of Medicine
E. J. Meyer Memorial Hospital
Buffalo, New York

A. M. LEFER
Jefferson Medical College
Department of Physiology
Philadelphia, Pennsylvania

M. D. LIFSCHITZ
University of Texas Health Science Center
Department of Medicine
San Antonio, Texas

F. H. LINCOLN
The Upjohn Company
Research Laboratories
Kalamazoo, Michigan

J. H. LUDENS
The Upjohn Company
Cardiovascular Diseases Research
Kalamazoo, Michigan

R. L. MAGOLDA
University of Pennsylvania
Department of Chemistry
Philadelphia, Pennsylvania

J. C. McGIFF
University of Tennessee
Center for the Health Sciences
Department of Pharmacology
Memphis, Tennessee

S. MONCADA
Wellcome Research Laboratories

Department of Prostaglandin Research
Langley Court
Kent
England

A. R. MORRISON
Washington University Medical School
Department of Pharmacology
St. Louis Missouri

A. NASJLETTI
University of Tennessee
Center for the Health Sciences
Department of Pharmacology
Memphis, Tennessee

P. NEEDLEMAN
Washington University Medical School
Department of Pharmacology
St. Louis, Missouri

K. C. NICOLAOU
University of Pennsylvania
Department of Chemistry
Philadelphia, Pennsylvania

K. NISHIKAWA
Washington University Medical School
Department of Pharmacology
St. Louis, Missouri

E. E. NISHIZAWA
The Upjohn Company
Research Laboratories
Kalamazoo, Michigan

J. A. OATES
Vanderbilt University
Department of Medicine
Nashville, Tennessee

M. L. OGLETREE
Jefferson Medical College
Department of Physiology
Philadelphia, Pennsylvania

H. G. OIEN
Merck Institute for Therapeutic Research
Rahway, New Jersey

C. R. PACE-ASCIAC
The Hospital for Sick Children
Research Institute
Toronto,
Canada

R. PATAK
University of Texas Health Science Center
Department of Medicine
San Antonio, Texas

E. PURE
Washington University Medical School
Department of Pharmacology
St. Louis, Missouri

E. R. RAMEY
Georgetown University Medical Center
Department of Physiology and Biophysics
Washington, D.C.

P. W. RAMWELL
Georgetown University Medical Center
Department of Physiology and Biophysics
Washington, D.C.

S. ROSENBLATT
University of Texas Health Science Center
Department of Medicine
San Antonio, Texas

H. F. RUSSO
Merck Institute for Therapeutic Research
West Point, Pennsylvania

B. SCHERER
University of Munich
Medizinische Klinik Innenstadt
Munich,
Germany

A. SCRIBABINE
Dome Labs
West Haven, Connecticut

W. K. SHUM
Merck Institute for Therapeutic Research
West Point, Pennsylvania

M. SIVAKOFF
Washington University Medical School
Department of Pharmacology
St. Louis, Missouri

J. B. SMITH
Jefferson Medical College
Department of Pharmacology
Philadelphia, Pennsylvania

W. L. SMITH
Michigan State University
Department of Biochemistry
East Lansing, Michigan

E. W. SPANNHAKKE
Tulane University School of Medicine
Department of Pharmacology
New Orleans, Louisiana

J. H. STEIN
University of Texas Health Science Center
Department of Medicine
San Antonio, Texas

J. B. STOKES
University of Texas Health Science Center
Southwestern Medical School
Department of Internal Medicine
Dallas, Texas

V. G. STYGLES
Michigan State University
Department of Pharmacology and Toxicology
East Lansing, Michigan

C. O. TACKET
Yale University School of Medicine
Cardiology Section
Department of Medicine
New Haven, Connecticut

C. J. TAYLOR
The Upjohn Company
Cardiovascular Diseases Research
Kalamazoo, Michigan

D. A. TERRAGNO
University of Tennessee
Center for the Health Sciences
Department of Pharmacology
Memphis, Tennessee

N. A. TERRAGNO
University of Tennessee
Center for the Health Sciences
Department of Pharmacology
Memphis, Tennessee

J. L. THOMPSON
The Upjohn Company
Research Laboratories
Kalamazoo, Michigan

J. R. VANE
Wellcome Research Laboratories
Department of Prostaglandin Research
Langley Court
Kent
England

L. S. WATSON
Merck Institute for Therapeutic Research
West Point, Pennsylvania

P. C. WEBER
University of Munich
Medizinische Klinik Innenstadt
Munich
Germany

M. G. WENDLING
The Upjohn Company
Cardiovascular Disease Research
Kalamazoo, Michigan

G. P. WILKIN
Michigan State University
Department of Biochemistry
East Lansing, Michigan

S. WOLFSON
Yale University School of Medicine
Cardiology Section
Department of Medicine
New Haven, Connecticut

R. M. ZUSMAN
Harvard Medical School
Massachusetts General Hospital
Medical Services
Boston, Massachusetts

Acknowledgments

The editors gratefully acknowledge the assistance of Ms. Janet Service, Merck Institute for Therapeutic Research, West Point, PA, in the organization of the symposium and preparation of this volume. Financial support for the symposium was provided by The Physiological Society of Philadelphia and the following contributors:

Abbot Laboratories
Ciba-Geigy Corporation
Dow Chemical Company
Hoechst-Roussel Pharmaceuticals, Inc.
Hoffmann-LaRoche, Inc.
ICI United States, Inc.
McNeil Laboratories, Inc.
Mead Johnson Research Center
Merck Sharp & Dohme Research Laboratories
Miles Laboratories, Inc.
Ortho Pharmaceutical Corp.
Pfizer, Inc.
Wm. H. Rorer, Inc.
Ross Laboratories
Schering Corporation
Smith Kline & French Laboratories
Squibb Institute for Medical Research
The Upjohn Company
USV Pharmaceutical Corp.
Wellcome Research Laboratories
Wyeth Laboratories

Introduction

This volume represents the edited version of the 20th Annual Alfred Newton Richards Symposium sponsored by The Physiological Society of Philadelphia and held on May 8-9, 1978 in King of Prussia, PA.

The selection of the topic for this symposium reflected recognition of the importance of recent discoveries of the role of prostaglandins in the control of cardiovascular and renal function.

The contributions by Vane, Pace-Asciak, Lefer, Sivakoff, DuCharme and Kadowitz emphasized the uniqueness of the cardiovascular effects of prostacyclin, a likely natural substance which protects from coronary heart disease and opposes the action of thromboxanes. This opens many new approaches to drug development including stable derivatives of prostacyclin and inhibitors of thromboxane synthetase.

An interdisciplinary approach to prostaglandin research was emphasized in the organization of this symposium. The participants included medicinal chemists, biochemists, physiologists, pharmacologists and clinicians. The symposium provided a forum for scientific interaction and extensive discussions of the presented results.

This volume will hopefully be useful not only to physiologists, pharmacologists and biochemists, but also to practicing physicians attempting to update their knowledge of the rapidly expanding field of prostaglandins as well as to medical and graduate students.

A. Scriabine

A.M. Lefer

F.A. Kuehl, Jr.

Contents

Introduction

PART I—CHEMISTRY

1. Chemistry of Prostaglandins and Prostacyclins
U. Axen, F. H. Lincoln, J. L. Thompson, T. Honohan and E. E. Nishizawa 3
2. Synthesis and Biological Properties of Prostacyclins
K. C. Nicolaou, W. E. Barnette and R. L. Magolda 9

PART II—BIOCHEMISTRY

3. Prostaglandin E-Related Actions of Drugs Regulating Renal Function
F. A. Kuehl, Jr., H. G. Oien and E. A. Ham31
4. Enhanced Aortic Synthesis and Vasodepressor Action of PGI₂ During Hypertension
C. R. Pace-Asciak and M. C. Carrara.....41
5. Biochemical Regulation and Pharmacological Manipulation of Renal Prostaglandin and Thromboxane Synthesis
P. Needleman, W. Hsueh, K. Nishikawa and A. R. Morrison53

Discussion 1 Session 2.....65

6. Cellular Distribution of Enzymes Involved in Prostaglandin Metabolism in the Mammalian Kidney
W. L. Smith, F. C. Grenier, T. G. Bell and G. P. Wilkin71
7. Regulation of Prostaglandin Biosynthesis: Studies in the Rabbit Renomedullary Interstitial Cell and the Toad Urinary Bladder *In Vitro*
R. M. Zusman.....93
8. Renomedullary Prostaglandin Biosynthesis: Dependence on Extracellular Potassium Concentration
R. Düsing and J. B. Lee123

Discussion 2 Session 2	139
------------------------------	-----

PART III—CARDIAC EFFECTS

9. Cardiac and Coronary Vascular Actions of Prostaglandins in Cats <i>M. L. Ogletree, J. B. Smith and A. M. Lefer</i>	145
10. Role of Prostaglandins E ₂ and F ₂ α During Myocardial Ischemia <i>C. O. Tacket, N. Good, H. J. Berger and S. Wolfson</i>	159
11. Preservation of Ischemic Myocardial Tissue by Prostaglandins <i>A. M. Lefer and M. L. Ogletree</i>	175

Discussion 1 Session 3	189
------------------------------	-----

12. Cardiovascular Synthesis of Prostacyclin and the Role of Vascular Injury <i>M. Sivakoff, E. Pure and P. Needleman</i>	193
13. The Prostaglandin–Thromboxane System and Coronary and Cerebral Arterial Smooth Muscle Tone <i>E. F. Ellis, H. A. Kontos and J. A. Oates</i>	209
14. Pharmacological Studies on the Role of Prostaglandins in Cardiac Hypersensitivity Reactions <i>G. Allan and R. Levi</i>	223

Discussion 2 Session 3	239
------------------------------	-----

15. Prostacyclin, Platelets and Vascular Disease <i>S. Moncada and J. R. Vane</i>	241
--	-----

PART IV—VASCULAR EFFECTS

16. Hemodynamic Activities of Prostacyclin (PGI ₂) as Compared to Other Products of the Arachidonic Acid Cascade <i>D. W. DuCharme, G. L. DeGraaf, S. J. Humphrey and M. G. Wendling</i>	265
17. Prostaglandin Synthesis and Renin Release in Relation to Salt Intake and Blood Pressure <i>P. C. Weber, R. Joppich and B. Scherer</i>	279
18. Prostaglandins and the Regulation of the Uterine Circulation During Pregnancy <i>N. A. Terragno, J. C. McGiff and A. Terragno</i>	307

Discussion 1 Session 4	317
------------------------------	-----

19. Relation Between the Renal Kallikrein-Kinin and Prostaglandin System: Possible Significance in the Regulation of Renal Function <i>A. Nasjletti and M. C. Blasingham</i>	321
---	-----

20. Cardiovascular Actions of Prostaglandin $F_2\alpha$ in the Cat <i>M. C. Koss</i>	335
21. Cardiopulmonary Effects of Prostacyclin (PGI_2) <i>P. J. Kadowitz, E. W. Spannhake, B. M. Chapnick, L. P. Feigen and A. L. Hyman</i>	351
22. Sex Differences in Vascular Responses to Arachidonic Acid <i>P. J. Baker, E. R. Ramey and P. W. Ramwell</i>	363
Discussion 2 Session 4	381

PART V—RENAL EFFECTS

23. Interactions of Renal Prostaglandins with the Renin-Angiotensin and Kallikrein-Kinin Systems <i>J. C. McGiff</i>	387
24. Aspects of Prostaglandin Release and Action on Adrenergic Neurotransmission in the Kidney <i>P. Hedqvist</i>	399
25. Factors Involved in the Regulation of Renal Prostaglandin E Production <i>M. D. Lifschitz, R. Patak, S. Fadem, S. Rosenblatt, T. Burns, M. Epstein and J. H. Stein</i>	407
26. Renal Tubular Sites of Action of Prostaglandins on Salt Transport <i>J. B. Stokes and J. P. Kokko</i>	425
Discussion 1 Session 5	439
27. Role of Prostaglandins in Collecting Duct Function <i>J. B. Hook and V. G. Stygles</i>	443
28. Role of Prostaglandins as Modulators of the Hydro-Osmotic Response to ADH <i>J. H. Ludens and C. J. Taylor</i>	457
29. Studies on the Interaction of Indomethacin with Various Diuretics <i>A. Scriabine, L. S. Watson, G. M. Fanelli, Jr., W. K. Shum, E. H. Blaine, H. F. Russo and N. R. Bohidar</i>	471
Discussion 2 Session 5	485
Index	487

Chemistry

